Standard
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction : GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. / Teerlink, John R.; Diaz, Rafael; Felker, G. Michael; McMurray, John J. V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias-Mendoza, Alexandra; Biering-Sorensen, Tor; Bohm, Michael; Bonderman, Diana; Cleland, John G. F.; Corbalan, Ramon; Crespo-Leiro, Maria G.; Dahlstrom, Ulf; Echeverria Correa, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Candida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin-ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J. A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Abbasi, Siddique A.; Varin, Claire; Malik, Fady I.; Kurtz, Christopher E.; GALACTIC HF Investigators.
I:
European Journal of Heart Failure, Bind 22, Nr. 11, 2020, s. 2160-2171.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Teerlink, JR, Diaz, R, Felker, GM, McMurray, JJV, Metra, M, Solomon, SD, Adams, KF, Anand, I, Arias-Mendoza, A
, Biering-Sorensen, T, Bohm, M, Bonderman, D, Cleland, JGF, Corbalan, R, Crespo-Leiro, MG, Dahlstrom, U, Echeverria Correa, LE, Fang, JC, Filippatos, G, Fonseca, C, Goncalvesova, E, Goudev, AR, Howlett, JG, Lanfear, DE, Lund, M, Macdonald, P, Mareev, V, Momomura, S, O'Meara, E, Parkhomenko, A, Ponikowski, P, Ramires, FJA, Serpytis, P, Sliwa, K, Spinar, J, Suter, TM, Tomcsanyi, J, Vandekerckhove, H, Vinereanu, D, Voors, AA, Yilmaz, MB, Zannad, F, Sharpsten, L, Legg, JC, Abbasi, SA, Varin, C, Malik, FI, Kurtz, CE & GALACTIC HF Investigators 2020, '
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials',
European Journal of Heart Failure, bind 22, nr. 11, s. 2160-2171.
https://doi.org/10.1002/ejhf.2015APA
Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A.
, Biering-Sorensen, T., Bohm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R., Crespo-Leiro, M. G., Dahlstrom, U., Echeverria Correa, L. E., Fang, J. C., Filippatos, G., ... GALACTIC HF Investigators (2020).
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
European Journal of Heart Failure,
22(11), 2160-2171.
https://doi.org/10.1002/ejhf.2015Vancouver
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD o.a.
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
European Journal of Heart Failure. 2020;22(11):2160-2171.
https://doi.org/10.1002/ejhf.2015Author
Teerlink, John R. ; Diaz, Rafael ; Felker, G. Michael ; McMurray, John J. V. ; Metra, Marco ; Solomon, Scott D. ; Adams, Kirkwood F. ; Anand, Inder ; Arias-Mendoza, Alexandra ; Biering-Sorensen, Tor ; Bohm, Michael ; Bonderman, Diana ; Cleland, John G. F. ; Corbalan, Ramon ; Crespo-Leiro, Maria G. ; Dahlstrom, Ulf ; Echeverria Correa, Luis E. ; Fang, James C. ; Filippatos, Gerasimos ; Fonseca, Candida ; Goncalvesova, Eva ; Goudev, Assen R. ; Howlett, Jonathan G. ; Lanfear, David E. ; Lund, Mayanna ; Macdonald, Peter ; Mareev, Vyacheslav ; Momomura, Shin-ichi ; O'Meara, Eileen ; Parkhomenko, Alexander ; Ponikowski, Piotr ; Ramires, Felix J. A. ; Serpytis, Pranas ; Sliwa, Karen ; Spinar, Jindrich ; Suter, Thomas M. ; Tomcsanyi, Janos ; Vandekerckhove, Hans ; Vinereanu, Dragos ; Voors, Adriaan A. ; Yilmaz, Mehmet B. ; Zannad, Faiez ; Sharpsten, Lucie ; Legg, Jason C. ; Abbasi, Siddique A. ; Varin, Claire ; Malik, Fady I. ; Kurtz, Christopher E. ; GALACTIC HF Investigators. / Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction : GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. I: European Journal of Heart Failure. 2020 ; Bind 22, Nr. 11. s. 2160-2171.
Bibtex
@article{68640ef632604503b909e5e31d5afbe2,
title = "Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials",
abstract = "Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fractionConclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.",
keywords = "Heart failure, Omecamtiv mecarbil, Cardiac myosin activator, Inotrope, Myotrope, Cardiovascular outcomes trial, CARDIAC MYOSIN ACTIVATOR, INCREASE CONTRACTILITY, TOLVAPTAN, MORTALITY, OUTCOMES, PHASE-2, WOMEN",
author = "Teerlink, {John R.} and Rafael Diaz and Felker, {G. Michael} and McMurray, {John J. V.} and Marco Metra and Solomon, {Scott D.} and Adams, {Kirkwood F.} and Inder Anand and Alexandra Arias-Mendoza and Tor Biering-Sorensen and Michael Bohm and Diana Bonderman and Cleland, {John G. F.} and Ramon Corbalan and Crespo-Leiro, {Maria G.} and Ulf Dahlstrom and {Echeverria Correa}, {Luis E.} and Fang, {James C.} and Gerasimos Filippatos and Candida Fonseca and Eva Goncalvesova and Goudev, {Assen R.} and Howlett, {Jonathan G.} and Lanfear, {David E.} and Mayanna Lund and Peter Macdonald and Vyacheslav Mareev and Shin-ichi Momomura and Eileen O'Meara and Alexander Parkhomenko and Piotr Ponikowski and Ramires, {Felix J. A.} and Pranas Serpytis and Karen Sliwa and Jindrich Spinar and Suter, {Thomas M.} and Janos Tomcsanyi and Hans Vandekerckhove and Dragos Vinereanu and Voors, {Adriaan A.} and Yilmaz, {Mehmet B.} and Faiez Zannad and Lucie Sharpsten and Legg, {Jason C.} and Abbasi, {Siddique A.} and Claire Varin and Malik, {Fady I.} and Kurtz, {Christopher E.} and {GALACTIC HF Investigators}",
year = "2020",
doi = "10.1002/ejhf.2015",
language = "English",
volume = "22",
pages = "2160--2171",
journal = "European Journal of Heart Failure",
issn = "1567-4215",
publisher = "JohnWiley & Sons Ltd",
number = "11",
}
RIS
TY - JOUR
T1 - Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction
T2 - GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
AU - Teerlink, John R.
AU - Diaz, Rafael
AU - Felker, G. Michael
AU - McMurray, John J. V.
AU - Metra, Marco
AU - Solomon, Scott D.
AU - Adams, Kirkwood F.
AU - Anand, Inder
AU - Arias-Mendoza, Alexandra
AU - Biering-Sorensen, Tor
AU - Bohm, Michael
AU - Bonderman, Diana
AU - Cleland, John G. F.
AU - Corbalan, Ramon
AU - Crespo-Leiro, Maria G.
AU - Dahlstrom, Ulf
AU - Echeverria Correa, Luis E.
AU - Fang, James C.
AU - Filippatos, Gerasimos
AU - Fonseca, Candida
AU - Goncalvesova, Eva
AU - Goudev, Assen R.
AU - Howlett, Jonathan G.
AU - Lanfear, David E.
AU - Lund, Mayanna
AU - Macdonald, Peter
AU - Mareev, Vyacheslav
AU - Momomura, Shin-ichi
AU - O'Meara, Eileen
AU - Parkhomenko, Alexander
AU - Ponikowski, Piotr
AU - Ramires, Felix J. A.
AU - Serpytis, Pranas
AU - Sliwa, Karen
AU - Spinar, Jindrich
AU - Suter, Thomas M.
AU - Tomcsanyi, Janos
AU - Vandekerckhove, Hans
AU - Vinereanu, Dragos
AU - Voors, Adriaan A.
AU - Yilmaz, Mehmet B.
AU - Zannad, Faiez
AU - Sharpsten, Lucie
AU - Legg, Jason C.
AU - Abbasi, Siddique A.
AU - Varin, Claire
AU - Malik, Fady I.
AU - Kurtz, Christopher E.
AU - GALACTIC HF Investigators
PY - 2020
Y1 - 2020
N2 - Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fractionConclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.
AB - Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fractionConclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.
KW - Heart failure
KW - Omecamtiv mecarbil
KW - Cardiac myosin activator
KW - Inotrope
KW - Myotrope
KW - Cardiovascular outcomes trial
KW - CARDIAC MYOSIN ACTIVATOR
KW - INCREASE CONTRACTILITY
KW - TOLVAPTAN
KW - MORTALITY
KW - OUTCOMES
KW - PHASE-2
KW - WOMEN
U2 - 10.1002/ejhf.2015
DO - 10.1002/ejhf.2015
M3 - Journal article
C2 - 32985088
VL - 22
SP - 2160
EP - 2171
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1567-4215
IS - 11
ER -
